Amarhyton belongs to the group of medicines that work against cardiac arrhythmia (known as anti-arrhythmics).
It inhibits stimulus conduction in the heart and extends the time during which the heart is at rest, causing the heart to pump normally again.
Amarhyton is used for:
- Treatment of AV nodal reciprocating tachycardia; arrhythmias associated with Wolff-Parkinson-White Syndrome and similar conditions with accessory pathways, when other treatment has been ineffective.
- Treatment of severe symptomatic and life-threatening paroxysmal ventricular arrhythmia which has failed to respond to other forms of therapy or where other treatments have not been tolerated.
- Treatment of paroxysmal atrial arrhythmias (atrial fibrillation, atrial flutter and atrial tachycardia) in patients with disabling symptoms after conversion provided that there is definite need for treatment on the basis of severity of clinical symptoms, when other treatment has been ineffective. Structural heart disease and/or impaired left ventricular function should be excluded because of the increased risk for pro-arrhythmic effects.
Subject to medical prescription
Pharmaceutical form: 50 mg prolonged-release capsules, hard
Pharmaceutical form: 100 mg prolonged-release capsules, hard
Pharmaceutical form: 150 mg prolonged-release capsules, hard
Pharmaceutical form: 200 mg prolonged-release capsules, hard
АТС code: C01 BC 04